Vol. 22/No. 17

The understanding of EGFR signaling in non–small cell lung cancer continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations.

Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.

Despite early induced efficacy first- and second-generation tyrosine kinase inhibitors have limited efficacy for patients with chronic myeloid leukemia.

Participating in a clinical trial is the most effective way to gain access to new and potentially better ways to treat cancer, yet we’ve seen a decrease in the number of African American and Hispanic patients participating in oncology trials in 2003 to 2016, compared with 1996 to 2002.

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

The achievements of Roman Perez-Soler, MD, include studies of anti-EGFR therapies and topoisomerase inhibitors, extensive research on liposomal delivery systems, and early work on patient-derived xenografts in mice.

Data from the phase 2 ROCKstar trial demonstrated that belumosudil induced clinically meaningful, durable responses in patients with chronic graft-vs-host disease, irrespective of previous treatment received, severity of disease, and number of organs involved.

It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.